Home NASDAQ: CFRX
0.5512
Price0.22%   +0.0012
 
loading

Contrafect Corporation Stock (CFRX) Latest News

thumbnail
pulisher
GlobeNewswire Inc.

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

thumbnail
pulisher
Benzinga

Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session

thumbnail
pulisher
GlobeNewswire Inc.

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

thumbnail
pulisher
GlobeNewswire Inc.

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

thumbnail
pulisher
Benzinga

Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session

thumbnail
pulisher
Benzinga

Why Kosmos Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

thumbnail
pulisher
GlobeNewswire Inc.

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million

thumbnail
pulisher
PennyStocks

Top Penny Stocks Trading Mistakes to Avoid 

thumbnail
pulisher
PennyStocks

Penny Stocks Trading and Options: Strategies for Leveraged Profits 

thumbnail
pulisher
Benzinga

Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session

thumbnail
pulisher
Benzinga

Why Sientra Shares Are Trading Higher By 84%; Here Are 20 Stocks Moving Premarket

thumbnail
pulisher
GlobeNewswire Inc.

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

thumbnail
pulisher
PennyStocks

Discover the Top Penny Stock Technical Indicators By Effectiveness

thumbnail
pulisher
Benzinga

Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

thumbnail
pulisher
Benzinga

Why Nevro Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

thumbnail
pulisher
Benzinga

Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

thumbnail
pulisher
Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
Cap:     |  Volume (24h):